Status:
COMPLETED
Bifeprunox in the Treatment of Schizophrenia
Lead Sponsor:
Solvay Pharmaceuticals
Conditions:
Schizophrenia
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
Study of the long-term efficacy and safety of bifeprunox in the treatment of schizophrenia. Extension to study S154.3.001.
Eligibility Criteria
Inclusion
- diagnosis of schizophrenia, understand nature of study, able to be managed in out-patient setting for long-term bifeprunox treatment
Exclusion
- current primary diagnosis other than schizophrenia, suicide risk, diagnosis or history of substance abuse, uncontrolled hypertension
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2008
Estimated Enrollment :
986 Patients enrolled
Trial Details
Trial ID
NCT00193687
Start Date
September 1 2005
End Date
January 1 2008
Last Update
March 24 2008
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.